These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24129559)

  • 1. In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease.
    Ikewaki K
    Clin Exp Nephrol; 2014 Apr; 18(2):261-4. PubMed ID: 24129559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
    Schwaiger JP; Nakada Y; Berberich R; Ikewaki K; Dieplinger B; Zitt E; Neyer U; Salmhofer H; Kronenberg F; Koenig P; Dieplinger H
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1319-26. PubMed ID: 23599405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
    Batista MC; Welty FK; Diffenderfer MR; Sarnak MJ; Schaefer EJ; Lamon-Fava S; Asztalos BF; Dolnikowski GG; Brousseau ME; Marsh JB
    Metabolism; 2004 Oct; 53(10):1255-61. PubMed ID: 15375779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status.
    Matthan NR; Jalbert SM; Lamon-Fava S; Dolnikowski GG; Welty FK; Barrett HR; Schaefer EJ; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1691-6. PubMed ID: 15933247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in lipoprotein composition in peritoneal dialysis patients.
    Moberly JB; Attman PO; Samuelsson O; Johansson AC; Knight-Gibson C; Alaupovic P
    Perit Dial Int; 2002; 22(2):220-8. PubMed ID: 11990407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased lipoprotein (a) and its relationships with other parameters of lipoprotein metabolism in chronic renal failure treated by hemodialysis.
    Yiğitoğlu MR; Polat MF; Akçay F; Ari Z; Uyanik BS; Ozilgili HM
    Jpn Heart J; 1997 Jan; 38(1):83-9. PubMed ID: 9186284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency.
    Ikewaki K; Cain W; Thomas F; Shamburek R; Zech LA; Usher D; Brewer HB; Rader DJ
    J Lipid Res; 2004 Jul; 45(7):1302-11. PubMed ID: 15102883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.
    Quaschning T; Krane V; Metzger T; Wanner C
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S14-9. PubMed ID: 11576915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients.
    Frischmann ME; Kronenberg F; Trenkwalder E; Schaefer JR; Schweer H; Dieplinger B; Koenig P; Ikewaki K; Dieplinger H
    Kidney Int; 2007 May; 71(10):1036-43. PubMed ID: 17299521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles.
    Bekaert ED; Alaupovic P; Knight-Gibson CS; Franceschini G; Sirtori CR
    J Lipid Res; 1993 Jan; 34(1):111-23. PubMed ID: 8445335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal lipoprotein metabolism in diabetic nephropathy.
    Hirano T
    Clin Exp Nephrol; 2014 Apr; 18(2):206-9. PubMed ID: 24132562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.
    Chan DC; Hoang A; Barrett PH; Wong AT; Nestel PJ; Sviridov D; Watts GF
    J Clin Endocrinol Metab; 2012 Sep; 97(9):E1658-66. PubMed ID: 22745238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
    Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.